IP Library › Granted Patent US 10,548,948
Granted Patent B2
US 10,548,948 · App. 15/906,863 · Granted Feb 4, 2020

Methods of treating fungal infections

Inventors: Nancy Millenbaugh (San Antonio, TX); Jeremy Wesley Gleaton (Cleveland, OH); Dickson Kiprono Kirui (San Antonio, TX)
Assignee: The United States of America as represented by the Secretary of the Navy
A61K38/1767A61K45/06A61L15/44A61P31/00A61L2300/252A61L2300/404
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,548,948
App. No.
15/906,863
Granted
Feb 4, 2020
Kind
B2
Abstract

Antifungal pharmaceutical compositions, dosage forms, and methods of use thereof are disclosed.

Claims (14)

1. A method of treating a fungal infection in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising one or more peptides selected from the group consisting of BmKn2, dBmKn2, Kn2-7, and dKn2-7, wherein said BmKn2 and said Kn2-7 peptides comprise combination of D form and L form amino acids.

2. A method of treating a fungal infection in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising one or more peptides selected from the group consisting of BmKn2, dBmKn2, Kn2-7, and dKn2-7, wherein the fungal infection is resistant t one or more conventional antifungal agents.

3. The method of claim 1 or claim 2 wherein the fungal infection is a planktonic or a biofilm fungal infection, or a combination thereof.

4. The method of claim 3 wherein the biofilm fungal infection comprises a pre-formed biofilm.

5. The method of claim 1 wherein the fungal infection is resistant to one or more conventional antifungal agents.

6. The method of claim 1 or claim 2 wherein the infection is a wound infection.

7. The method of claim 1 or claim 2 wherein the pharmaceutical composition is administered alone, or in combination with a therapeutically effective amount of one or more additional pharmaceutically acceptable agents.

8. The method of claim 7 wherein the one or more additional pharmaceutically acceptable agents is selected from the group consisting of an antimicrobial agent, an analgesic, a wound healing agent, a biofilm dispersal agent, and a biofilm inhibitor agent.

9. The method of claim 8 wherein the antimicrobial agent is selected from the group consisting of an antifungal agent, an antibacterial agent, and an antiviral agent.

10. The method of claim 1 or claim 2 wherein the peptide is dKn2-7.

11. The method of claim 1 or claim 2 wherein the fungal infection is caused by Candida.

12. The method of claim 11 wherein the fungal infection is caused by Candida albicans.

13. The method of claim 8 wherein the additional pharmaceutically acceptable agent is a wound healing agent.

14. The method of claim 13 wherein the wound healing agent is an alginate.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2018
From: GLEATON, JEREMY
To: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY
Reel/Frame 045059/0078 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2018
From: KIRUI, DICKSON K
To: CAMRIS INTERNATIONAL
Reel/Frame 045059/0232 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2018
From: CAMRIS INTERNATIONAL
To: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY
Reel/Frame 045059/0359 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2018
From: MILLENBAUGH, NANCY
To: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY
Reel/Frame 045059/0466 →
Continuity (3)
Provisional Application 62466195 · Mar 2, 2017
Provisional Application 62548506 · Aug 22, 2017
Related Publication 20180250362A1 · Sep 6, 2018